FibroGen, Inc (FGEN) financial statements (2020 and earlier)
Company profile
| Business Address |
409 ILLINOIS STREET SAN FRANCISCO, CA 94158 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 534 | 629 | 661 | 565 | 621 | 653 | 672 | ||
| Cash and cash equivalents | 126 | 197 | 75 | 82 | 89 | 567 | 644 | ||
| Short-term investments | 407 | 432 | 586 | 484 | 532 | 86 | 28 | ||
| Receivables | 154 | 145 | 134 | 10 | 64 | 23 | 45 | ||
| Inventory, net of allowances, customer advances and progress billings | 7 | 5 | 2 | ||||||
| Inventory | 7 | 5 | 2 | ||||||
| Prepaid expense | 6 | 4 | 5 | ||||||
| Other current assets | 2 | 4 | 4 | ||||||
| Other undisclosed current assets | 4 | 5 | 3 | 3 | |||||
| Total current assets: | 702 | 786 | 806 | 579 | 690 | 679 | 720 | ||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset | 40 | 42 | 45 | ✕ | ✕ | ✕ | |||
| Operating lease, right-of-use asset | 2 | 2 | 1 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 43 | 43 | 45 | 46 | 127 | 128 | 129 | ||
| Long-term investments and receivables | 61 | 11 | 11 | 132 | 56 | 41 | 11 | ||
| Long-term investments | 61 | 11 | 11 | 132 | 56 | 41 | 11 | ||
| Other noncurrent assets | 9 | 7 | 5 | 4 | 3 | 3 | 5 | ||
| Other undisclosed noncurrent assets | 0 | 2 | 3 | 51 | 4 | 5 | 5 | ||
| Total noncurrent assets: | 155 | 107 | 109 | 233 | 191 | 177 | 150 | ||
| TOTAL ASSETS: | 857 | 894 | 915 | 812 | 881 | 856 | 870 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6 | 4 | 4 | 70 | 75 | 63 | 53 | ||
| Accounts payable | 6 | 4 | 4 | 4 | 9 | 10 | 3 | ||
| Accrued liabilities | 66 | 66 | 53 | 49 | |||||
| Deferred revenue | 0 | 0 | 0 | ✕ | ✕ | ✕ | |||
| Debt | 12 | 12 | 12 | ||||||
| Due to related parties | 1 | 0 | |||||||
| Contract with customer, liability | ✕ | ✕ | ✕ | 12 | 14 | 38 | |||
| Other undisclosed current liabilities | 84 | 71 | 67 | 11 | 38 | ||||
| Total current liabilities: | 103 | 87 | 83 | 94 | 89 | 100 | 91 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 38 | 42 | 44 | ||||||
| Finance lease, liability | 38 | 41 | 44 | ✕ | ✕ | ✕ | |||
| Operating lease, liability | 1 | 0 | ✕ | ✕ | ✕ | ||||
| Liabilities, other than long-term debt | 164 | 135 | 122 | 145 | 149 | 150 | 13 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 3 | ||
| Deferred revenue | 99 | 99 | 103 | ✕ | ✕ | ✕ | |||
| Contract with customer, liability | ✕ | ✕ | ✕ | 135 | 136 | 137 | |||
| Deferred rent credit | 3 | 3 | |||||||
| Other liabilities | 64 | 36 | 19 | 10 | 10 | 10 | 9 | ||
| Other undisclosed noncurrent liabilities | 18 | 16 | 18 | 65 | 114 | 114 | 252 | ||
| Total noncurrent liabilities: | 219 | 193 | 184 | 210 | 263 | 265 | 265 | ||
| Total liabilities: | 322 | 280 | 267 | 304 | 352 | 365 | 355 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 516 | 594 | 629 | 489 | 509 | 471 | 496 | ||
| Common stock | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Additional paid in capital | 1,301 | 1,280 | 1,266 | 1,242 | 1,226 | 1,210 | 1,192 | ||
| Accumulated other comprehensive loss | (1) | (0) | (0) | (1) | (2) | (3) | (3) | ||
| Accumulated deficit | (785) | (687) | (637) | (753) | (716) | (737) | (694) | ||
| Stockholders' equity attributable to noncontrolling interest | 19 | 19 | 19 | 19 | 19 | 19 | 19 | ||
| Total stockholders' equity: | 535 | 614 | 648 | 508 | 528 | 491 | 515 | ||
| TOTAL LIABILITIES AND EQUITY: | 857 | 894 | 915 | 812 | 881 | 856 | 870 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 8 | 33 | 192 | 24 | 108 | 29 | 44 | |
| Operating expenses | (108) | (86) | (79) | (73) | (88) | (72) | (67) | |
| Operating income (loss): | (100) | (53) | 113 | (49) | 20 | (43) | (23) | |
| Interest and debt expense | (1) | (1) | (1) | (1) | (3) | (3) | (3) | |
| Income (loss) from continuing operations before equity method investments, income taxes: | (101) | (54) | 112 | (50) | 17 | (46) | (26) | |
| Other undisclosed income from continuing operations before income taxes | 3 | 4 | 4 | 4 | 4 | 3 | 3 | |
| Income (loss) from continuing operations before income taxes: | (98) | (49) | 116 | (45) | 21 | (42) | (23) | |
| Income tax expense (benefit) | (0) | (0) | (0) | 0 | (0) | (0) | (0) | |
| Net income (loss) available to common stockholders, diluted: | (98) | (49) | 116 | (45) | 21 | (43) | (23) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (98) | (49) | 116 | (45) | 21 | (43) | (23) | |
| Other comprehensive income (loss) | (1) | 0 | 0 | 1 | 0 | 0 | 1 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (99) | (49) | 116 | (45) | 21 | (43) | (22) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.